Halozyme Therapeutics (NASDAQ:HALO) Earns “Buy” Rating from HC Wainwright

Halozyme Therapeutics (NASDAQ:HALO – Get Free Report)‘s stock had its “buy” rating restated by HC Wainwright in a report issued on Friday, Marketbeat reports. They presently have a $130.00 price target on the biopharmaceutical company’s stock. HC Wainwright‘s target price indicates a potential upside of 42.31% from the company’s current price.

A number of other equities analysts have also recently weighed in on HALO. Wall Street Zen cut shares of Halozyme Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Saturday, November 7th. Leerink Partners lowered shares of Halozyme Therapeutics from an “outperform” rating to a “hold” rating and boosted their price target for the company from $110.00 to $117.00 in a report on Friday, November 6th. Wells Fargo & Company upped their price objective on shares of Halozyme Therapeutics from $95.00 to $110.00 and gave the company an “equal weight” rating in a research report on Friday, November 6th. JPMorgan Chase & Co. raised their price objective on Halozyme Therapeutics from $78.00 to $79.00 and gave the stock a “neutral” rating in a research note on Tuesday, November 3rd. Finally, Zacks Research downgraded Halozyme Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, November 11th. Seven analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Halozyme Therapeutics currently has an average rating of “Hold” and a consensus price target of $110.17.

Check Out Our Latest Report on HALO

Halozyme Therapeutics Stock Performance

Shares of NASDAQ:HALO opened at $91.35 on Friday. The firm’s 50 day simple moving average is $113.21 and its 200 day simple moving average is $86.03. Halozyme Therapeutics has a fifty-two week low of $61.22 and a fifty-two week high of $134.00. The company has a market capitalization of $10.41 billion, a price-to-earnings ratio of 23.24, a P/E/G ratio of 0.34 and a beta of 0.92. The company has a debt-to-equity ratio of 13.50, a current ratio of 3.88 and a quick ratio of 3.60.

Halozyme Therapeutics (NASDAQ:HALO – Get Free Report) last issued its quarterly earnings data on Thursday, November 5th. The biopharmaceutical company reported $2.39 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.30 by $0.09. Halozyme Therapeutics had a net margin of 26.93% and a return on equity of 751.81%. The firm had revenue of $492.97 million during the quarter, compared to analysts’ expectations of $491.63 million. During the same quarter in the previous year, the company earned $1.72 earnings per share. The business’s revenue for the quarter was up 39.1% on a year-over-year basis. As a group, sell-side analysts forecast that Halozyme Therapeutics will post 8.34 earnings per share for the current year.

Insider Buying and Selling

In other Halozyme Therapeutics news, Director Matthew Posard sold 5,000 shares of the firm’s stock in a transaction that occurred on Wednesday, November 18th. The shares were sold at an average price of $96.43, for a total transaction of $482,150.00. Following the sale, the director directly owned 48,609 shares in the company, valued at approximately $4,687,365.87. This trade represents a 9.33% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Helen Torley sold 20,000 shares of Halozyme Therapeutics stock in a transaction that occurred on Monday, November 16th. The shares were sold at an average price of $98.38, for a total transaction of $1,967,600.00. Following the completion of the transaction, the chief executive officer directly owned 767,780 shares in the company, valued at approximately $75,534,196.40. The trade was a 2.54% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 149,226 shares of company stock valued at $15,744,643. 2.50% of the stock is owned by company insiders.

Institutional Investors Weigh In On Halozyme Therapeutics

Institutional investors have recently added to or reduced their stakes in the stock. MidFirst Bank acquired a new position in Halozyme Therapeutics in the 2nd quarter worth $27,000. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new stake in shares of Halozyme Therapeutics in the 2nd quarter valued at about $28,000. Quantbot Technologies LP acquired a new stake in shares of Halozyme Therapeutics in the 2nd quarter valued at about $30,000. CoreCap Advisors LLC raised its stake in shares of Halozyme Therapeutics by 98.0% in the 3rd quarter. CoreCap Advisors LLC now owns 303 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 150 shares during the period. Finally, Hilton Head Capital Partners LLC acquired a new stake in shares of Halozyme Therapeutics in the 3rd quarter valued at about $33,000. 97.79% of the stock is owned by institutional investors.

Trending Headlines about Halozyme Therapeutics

Here are a few of the latest headlines about HALO:

  • Positive Sentiment: HC Wainwright reaffirmed its buy rating and set a $130 price target, suggesting substantial upside from the cited share price. HC Wainwright ratings
  • Neutral Sentiment: JPMorgan raised its target to $81 from $79 but maintained a neutral rating; the new target is below the cited share price, signaling a more cautious view. JPMorgan ratings
  • Negative Sentiment: A German court overturned the preliminary injunction that had blocked Merck from offering its subcutaneous Keytruda product in Germany. Halozyme says it will pursue a permanent patent case, but the ruling removes an immediate barrier to Merck’s launch and adds uncertainty to the dispute’s potential commercial impact. Report on German court ruling

Halozyme Therapeutics Company Profile

(Get Free Report)

Halozyme Therapeutics, Inc. is a biotechnology company focused on developing drug-delivery technologies and medicines. Its ENHANZE platform uses a recombinant human hyaluronidase enzyme, rHuPH20, to temporarily modify tissue under the skin and help enable the subcutaneous administration of certain biologic medicines that might otherwise require intravenous infusion. Halozyme licenses ENHANZE to pharmaceutical and biotechnology partners, which use the technology in their own products. The company also markets Hylenex recombinant, a hyaluronidase product used to facilitate the dispersion and absorption of other injected medicines and fluids.

Recommended Stories

Analyst Recommendations for Halozyme Therapeutics (NASDAQ:HALO)

Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.